Bio printing Could be the New Solution to Organ Transplantation
3D technology is proving that the future looks quite different, with tissue engineering taking center stage, anticipating a possible future where organ transplants will not be needed to survive.
The company, one of the first big players in bioprinting, was founded in 2007 by Keith Murphy and Gabor Forgacs with a focus on developing in vivo liver tissues to treat a range of rare, life-threatening diseases, for which there are few current treatment options other than organ transplantation. Organovo’s ultimate goal in developing their liver therapeutic tissue is to delay or reduce the need for a transplant. The firm is also trying to harness their foundational ability to characterize specialized human cells and to 3D bioprint functional tissues to create novel in vitro toxicology and liver disease modeling platforms.
International Conference on Organ Donation and Transplantation Science
July 15-16, 2019 Sydney, Australia
Please visit: https://world.geneticconferences.com/